As above; the others don't exclude subjects, although they may have preferred or required subjects.
Most drug trials explicitly exclude subjects deemed a suicide risk; even when they don't, the studies don't last long enough to say anything definitive about who commits suicide.
Nevertheless, most contraceptive clinical trials exclude subjects with chronic medical conditions, and direct evidence on which to base sound contraceptive prescribing is limited.
Additional analyses were performed on sub-samples filtered to exclude subjects who had anomalous nicotine values, either very high pre-drug administration nicotine(i.e., >9 mg/ml), or anomalous post-nicotine values (i.e., no increase or a decrease in nicotine blood level values).
Strict criteria were used to exclude subjects with known angiogenic diseases to minimize confounding results.
We did not specifically include or exclude subjects with a known history of depression or anxiety.
In order to exclude subjects with overweight or obesity, weight and height were measured and BMI was calculated.
The EQUIP study is the only phase III trial that did not specifically exclude subjects with extreme obesity (i.e., BMI ≥ 45).
All subjects completed the Beck Depression Inventory, the Mini-Mental State Examination, the Symptoms Checklist, and Snaith-Hamilton Pleasure Scale before inclusion to exclude subjects with severe neuropsychiatric problems.
Controls were evaluated in the same manner as cases to exclude subjects with ASD or other developmental disturbances.
It was, therefore, essential that we exclude subjects who could not consistently respond "true" or "false" with conviction.
